
|Articles|September 1, 2016
- Pharmaceutical Executive-09-01-2016
- Volume 36
- Issue 9
Pharmaceutical Executive, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Pharm Exec's Emerging Pharma Leaders 2016over 9 years ago
Emerging Leaders 2016: Lessons from the Front Benchalmost 10 years ago
Patient-Centered Strategies for Clinical Trials & Treatmentalmost 10 years ago
Rise of the Vox Populialmost 10 years ago
Opioid Epidemic Prompts More Finger Pointing at Pharmaalmost 10 years ago
Country Report: France, Part IIAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5



